"Top level conference" - WTF is that?
One that includes international experts and the associate minister for health, Jim Anderton.
"Doug Sellman, a drug researcher" - HOW does he research drugs?
Professor Doug Sellman (Director) MBChB PhD FRANZCP FAChAM
Doug graduated MBChB from the University of Otago in 1980 and then completed postgraduate training in psychiatry in Christchurch, New Zealand, gaining his FRANZCP in 1987. He was appointed as Senior Lecturer in the Department of Psychological Medicine at the Christchurch School of Medicine in 1991 and research subsequently led to the completion of a PhD under the supervision of Professor Peter Joyce on the topic of "Alcoholic Relapse", in 1997. He was promoted to a Personal Chair in Psychiatry and Addiction Medicine in 2005 and was a foundation member of the Australasian Chapter of Addiction Medicine in 2002.
He took a leading role in the successful tendering for the National Addiction Centre (formerly known as the National Centre for Treatment Development (Alcohol, Drugs & Addiction) and has been Director of the Centre from its outset in 1996.
Collaborating with colleagues and supervising research students, he is currently involved in a full range of alcohol, drug and addiction related projects. Doug has been active in the development of alcohol and drug teaching at the Christchurch School of Medicine & Health Sciences over the past fifteen years. He developed a two-week inter-departmental block course for fifth-year medical students which has been running since 1995. He has also been instrumental in the development of a Postgraduate Diploma in Addiction & Co-existing Disorders through the University of Otago, which is now available nationally to a multidisciplinary group of students.
His clinical work since graduation as a psychiatrist in 1987 has been in the alcohol and drug area, and since 1994 he has been consultant to the alcohol and drug stream of the Youth Specialty Service in Christchurch, a specialist mental health service for people aged 13-18 years.
He is an enthusiastic member of the Harewood Golf Course in Christchurch and an active opponent of dieting, gym attendance and declaring war on anything.
Why not ask him scumdog? doug.sellman@otago.ac.nz. Looks well educated to me?
"Professor David Nutt an international drug expert" Mwhahaha! what qualifications does HE have?
Research
David Nutt heads the Psychopharmacology Unit in the Faculty of Medicine and Dentistry. The Unit integrates basic and clinical research to both study normal brain function, and to determine how it differs in psychiatric disorders such as clinical depression.
Experimental approaches range from receptor binding assays to collecting images of the human brain. The techniques in use include CT (Computerised Tomography), PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography).
PET is particularly useful in studying the effects of drugs and brain neurochemistry. Using different compounds, PET shows blood flow, oxygen and glucose metabolism, and the concentration of drugs or neurotransmitters. Blood flow and oxygen and glucose metabolism reflect the amount of brain activity in different regions, whilst determining the site and turnover of drugs and neurotransmitters gives insights into how they act in the brains of patients and in normal subjects.
David's particular areas of research focus on brain circuits and receptors in anxiety and addiction, and on the pharmacology of sleep.
This involves the study of GABA receptors, using labelled subtypes of GABA 5, and serotonin, or 5-HT, receptors. Type 1 5-HT receptors seem to be especially important in depression and the action of anti-depressants. Other projects underway investigate different aspects of anxiety, addiction and sleep.
Through its work, the Unit gains greater understanding of brain biology and how current treatments exert their effects. Based on these studies it is able to develop new drugs and treatment strategies, and the Unit is at the forefront in addressing how to combat conditions such as drug addiction and alcoholism. These and other disorders have major consequences for the individual and across the whole of society.
Current projects include:
- GABA and 5-HT1A receptors in anxiety using PET
- Dopamine and opiate receptors in addiction
Possible future projects and direction of research:
- Stress regulation
- Human models of anxiety
Diseases related to this field of research
Clinical depression, drug addiction, insomnia, anxiety and panic disorders, alcoholism, agoraphobia, social phobia
Processes and functions relevant to this work
Neurotransmission in the brain, sleep
Techniques in routine use
PET (Positron Emission Tomography) scanning, CO
2 challenge tests, Tryptophan depletion, challenge tests
Equipment in routine use
EEG (Electroencephalography), PET scanner, (Positron Emisssion Tomography), SPECT (Single Photon Emission Computed Tomography)
Top
Projects - Diseases - Processes - Techniques - Equipment - Funding - Collaborations - Teaching - Publications & further information
Top
Grants and funding
Wellcome Trust, Industry
Collaborations
- The Division of Psychiatry (GENPOD project: GENetic Predictors Of Depression)
- HW LINE
- O&G (Theranostics)
Teaching
I teach on the MRC Psychology course, and lecture both nationally and internationally.
Top
Publications, recommended reading and further information
Recent selected references
Davies SJ, Lowry CA, Nutt DJ.
Panic and hypertension: brothers in arms through 5-HT?
J Psychopharmacol. 2007 Aug;21(6):563-6.
Williams TM, Daglish MR, Lingford-Hughes A, Taylor LG, Hammers A, Brooks DJ, Grasby P, Myles JS, Nutt DJ.
Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study.
Br J Psychiatry. 2007 Jul;191:63-9.
Bailey JE, Papadopoulos A, Lingford-Hughes A, Nutt DJ.
D-Cycloserine and performance under different states of anxiety in healthy volunteers.
Psychopharmacology (Berl). 2007 Sep;193(4):579-85.
Nutt DJ, Kessler RC, Alonso J, Benbow A, Lecrubier Y, Lepine JP, Mechanic D, Tylee A.
Consensus statement on the benefit to the community of ESEMeD (European Study of the Epidemiology of Mental Disorders) survey data on depression and anxiety.
J Clin Psychiatry. 2007;68 Suppl 2:42-8.
Robinson HM, Hood SD, Bell CJ, Nutt DJ.
Dopamine and social anxiety disorder.
Rev Bras Psiquiatr. 2006 Dec;28(4):263-4.
Kalueff AV, Nutt DJ.
Role of GABA in anxiety and depression.
Depress Anxiety. 2007;24(7):495-517. Review.
Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S; British Association for Psychopharmacology.
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.
J Psychopharmacol. 2007 Jan;21(1):10-41.
Nutt DJ, Stein DJ.
Understanding the neurobiology of comorbidity in anxiety disorders.
CNS Spectr. 2006 Oct;11(10 Suppl 12): Please find further details of our research at the
Not much by the look of it!
Bookmarks